SCHEMBL130435

SCHEMBL130435

CCC=CCCOC(=O)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.64
TDP1 Q9NUW8 3/20 0.58
TSHR P16473 3/20 0.47
MAPK1 P28482 2/20 0.47
SLC6A2 P23975 2/20 0.47
HIF1A Q16665 1/20 0.47
SLC6A3 Q01959 1/20 0.47
KMT2A Q03164 1/20 0.47
F2 P00734 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
ALDH1A1 P00352 3/20 0.46
ESR1 P03372 2/20 0.45
CHRM1 P11229 1/20 0.45
KDR P35968 1/20 0.45
PKM P14618 1/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
GAA P10253 1/20 0.44
ESR2 Q92731 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL130434 1.00 LMNA (0.64) LMNATDP1TSHRMAPK1SLC6A2
SCHEMBL1771682 1.00 LMNA (0.64) LMNATDP1TSHRMAPK1SLC6A2
Benzoic Acid SCHEMBL1864558 0.95 LMNA (0.58) LMNATDP1TSHRMAPK1SLC6A2
(Z)-Hex-3-En-1-Yl Acetate SCHEMBL28969715 0.94 LMNA (0.57) LMNATDP1TSHRMAPK1SLC6A2
SCHEMBL30285512 0.90 LMNA (0.69) LMNATDP1TSHRMAPK1SLC6A2
SCHEMBL3751591 0.89 TDP1 (0.67) LMNATDP1TSHRMAPK1SMN1; SMN2
SCHEMBL3751588 0.89 TDP1 (0.67) LMNATDP1TSHRMAPK1SMN1; SMN2
SCHEMBL27491796 0.88 TDP1 (0.65) LMNATDP1TSHRMAPK1KMT2A
Ethyl Benzoate SCHEMBL29361886 0.86 LMNA (0.48) LMNATDP1TSHRMAPK1KMT2A
SCHEMBL30853560 0.85 LMNA (0.48) LMNATDP1TSHRMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 540 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4581114-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Novozymes A/S (DK) 2025-07-09 EP claimed
US-20250129312-A1 CONSUMER PRODUCT COMPOSITIONS WITH PERFUME ENCAPSULATES PROCTER & GAMBLE (US) 2025-04-24 US claimed
US-12209232-B2 Consumer product compositions with perfume encapsulates THE PROCTER & GAMBLE COMPANY (US) 2025-01-28 US claimed
EP-3689849-B1 PERFUME PRECURSOR TAKASAGO PERFUMERY CO LTD (JP) 2025-01-15 EP claimed
WO-2024213536-A1 FRAGRANCE COMPOSITION GIVAUDAN SA (CH) 2024-10-17 WO claimed
EP-4446001-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Givaudan SA (CH) 2024-10-16 EP claimed
EP-4438065-A2 A MIXTURE COMPRISING 1,2-ALKANEDIOLS Symrise AG (DE) 2024-10-02 EP claimed
US-20240306688-A1 METHOD OF MITIGATING OFF-ODORS GIVAUDAN SA (CH) 2024-09-19 US claimed
EP-4391827-A1 METHOD OF MITIGATING OFF-ODORS Givaudan SA (CH) 2024-07-03 EP claimed
WO-2024046952-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS NOVOZYMES A/S (DK) 2024-03-07 WO claimed
EP-2512406-A1 PERFUMES AND PERFUME ENCAPSULATES The Procter & Gamble Company (US) 2012-10-24 EP claimed
WO-2011075556-A1 COMPOSITION COMPRISING ENCAPSULATES, AND PROCESS FOR MAKING THEM THE PROCTER & GAMBLE COMPANY (US) 2011-06-23 WO claimed
WO-2011075551-A1 PERFUMES AND PERFUME ENCAPSULATES THE PROCTER & GAMBLE COMPANY (US) 2011-06-23 WO claimed
US-20110020516-A1 JASMINUM SAMBAC-LIKE FRAGRANCE COMPOSITION SHISEIDO COMPANY LTD. (JP) 2011-01-27 US claimed
US-20100247475-A1 BETA-GLUCURONIDASE INHIBITOR KAO CORPORATION (JP) 2010-09-30 US claimed
EP-2196525-A1 JASMINUM SAMBAC-LIKE FRAGRANCE COMPOSITION Shiseido Company, Ltd. (JP) 2010-06-16 EP claimed
EP-2192178-A1 B-GLUCURONIDASE INHIBITOR Kao Corporation (JP) 2010-06-02 EP claimed
US-4151309-A FOODS, CHEWING GUM, DENTIFRICES, DRUGS INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 1979-04-24 US claimed
US-4136208-A FLAVORING WITH SUBSTITUTED NORBORNANE DERIVATIVES INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 1979-01-23 US claimed
US-4076853-A Flavoring with substituted norbornane derivatives INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 1978-02-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100247475-A1 BETA-GLUCURONIDASE INHIBITOR GUSB, GAA, GANAB LMNA 3810/4885TDP1 3333/4885TSHR 3938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.